Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies.

Trial Profile

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Alemtuzumab (Primary) ; Clofarabine (Primary) ; Melphalan (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Lymphoid leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jul 2012 Planned End Date changed from 1 Dec 2016 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 09 Jul 2012 Planned End Date changed from 1 Dec 2016 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 25 Jun 2012 Planned End Date changed from 1 Dec 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top